KPIs & Operating Metrics(New)
Growth Metrics

Johnson & Johnson (JNJ) Total Non-Current Liabilities (2009 - 2026)

Johnson & Johnson recorded quarterly Total Non-Current Liabilities of $119.2 billion in Q1 2026, up 1.74% quarter-over-quarter from $117.2 billion in Q4 2025, and up 4.28% year-over-year from $114.3 billion in Q1 2025.

Johnson & Johnson's Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $119.2 billion for Q1 2026.

  • In Q1 2026, Total Non-Current Liabilities rose 4.28% year-over-year to $119.2 billion; the TTM figure through Mar 2026 stood at $119.2 billion (up 4.28% YoY), while the FY2025 annual figure was $117.2 billion, up 9.11% from the prior year.
  • Total Non-Current Liabilities came in at $119.2 billion for Q1 2026 at Johnson & Johnson, up from $117.2 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $124.0 billion in Q2 2023 to a low of $93.7 billion in Q4 2023.
  • A 5-year average of $107.4 billion and a median of $107.2 billion in 2024 frame the typical range for Total Non-Current Liabilities.
  • Across the five-year window, Total Non-Current Liabilities rose 20.16% in 2023 and slipped 18.66% in 2024, its largest moves.
  • Johnson & Johnson's Total Non-Current Liabilities stood at $100.0 billion in 2022, then decreased by 2.31% to $97.7 billion in 2023, then increased by 9.93% to $107.4 billion in 2024, then climbed by 9.11% to $117.2 billion in 2025, then climbed by 1.74% to $119.2 billion in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $119.2 billion, $117.2 billion, and $103.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - 100.00 Mn
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 48.74 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 119.22 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 108.96 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 75.11 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 80.55 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 31.56 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 113.51 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 61.52 Bn
10 Gsk 88.34 Bn 83.66 Bn - 31.62 Bn

Historic Data

Download Data 🔒
DateValue
Mar 29, 2026 119.22 Bn
Dec 28, 2025 117.18 Bn
Sep 28, 2025 103.61 Bn
Jun 29, 2025 104.65 Bn
Mar 30, 2025 114.33 Bn
Dec 29, 2024 107.40 Bn
Sep 29, 2024 106.91 Bn
Jun 30, 2024 108.30 Bn
Mar 31, 2024 100.83 Bn
Dec 31, 2023 97.69 Bn
Oct 1, 2023 93.66 Bn
Jul 2, 2023 114.14 Bn
Apr 2, 2023 123.96 Bn
Jan 1, 2023 109.45 Bn
Oct 2, 2022 100.00 Bn
Jul 3, 2022 100.83 Bn
Apr 3, 2022 103.16 Bn
Jan 2, 2022 107.46 Bn
Oct 3, 2021 108.34 Bn
Jul 4, 2021 106.27 Bn
Apr 4, 2021 106.12 Bn
Jan 3, 2021 110.98 Bn
Sep 27, 2020 105.58 Bn
Jun 28, 2020 94.61 Bn
Mar 29, 2020 82.78 Bn
Dec 29, 2019 96.54 Bn
Sep 29, 2019 95.67 Bn
Jun 30, 2019 92.77 Bn
Mar 31, 2019 90.62 Bn
Dec 30, 2018 92.81 Bn
Sep 30, 2018 82.54 Bn
Jul 1, 2018 83.20 Bn
Apr 1, 2018 84.49 Bn
Dec 31, 2017 96.54 Bn
Oct 1, 2017 72.58 Bn
Jul 2, 2017 70.77 Bn
Apr 2, 2017 65.05 Bn
Jan 1, 2017 61.25 Bn
Oct 2, 2016 58.19 Bn
Jul 3, 2016 57.28 Bn
Apr 3, 2016 53.84 Bn
Jan 3, 2016 52.02 Bn
Sep 27, 2015 52.41 Bn
Jun 28, 2015 51.93 Bn
Mar 29, 2015 52.11 Bn
Dec 28, 2014 52.57 Bn
Sep 28, 2014 47.75 Bn
Jun 29, 2014 49.78 Bn
Mar 30, 2014 49.48 Bn
Dec 29, 2013 50.78 Bn
Sep 29, 2013 48.23 Bn
Jun 30, 2013 46.09 Bn
Mar 31, 2013 46.48 Bn
Dec 30, 2012 47.97 Bn
Sep 30, 2012 45.98 Bn
Jul 1, 2012 45.83 Bn
Apr 1, 2012 44.29 Bn
Jan 1, 2012 45.93 Bn
Oct 2, 2011 42.82 Bn
Jul 3, 2011 42.76 Bn
Apr 3, 2011 41.29 Bn
Jan 2, 2011 39.76 Bn
Oct 3, 2010 34.73 Bn
Jul 4, 2010 33.09 Bn
Apr 4, 2010 34.48 Bn
Jan 3, 2010 38.15 Bn
Sep 27, 2009 36.12 Bn
Jun 28, 2009 36.92 Bn